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CteG is a Chlamydia trachomatis 
effector protein that associates 
with the Golgi complex of infected 
host cells
Sara V. pais1, Charlotte E. Key2, Vítor Borges  3, Inês S. Pereira  1, João Paulo Gomes  3, 
Derek J. Fisher  2 & Luís Jaime Mota  1
Chlamydia trachomatis is a bacterial pathogen causing ocular and genital infections in humans. C. 
trachomatis multiplies exclusively inside host cells within a characteristic vacuole, from where it 
manipulates host cells by injecting them with type III secretion effector proteins. Here, we identified 
CteG as the first C. trachomatis effector associated with the Golgi. For this, C. trachomatis strains 
expressing candidate effectors fused to a double hemagglutinin (2HA) tag were constructed. Then, 
among these strains, immunofluorescence microscopy revealed that CteG-2HA was delivered into the 
cytoplasm of infected cells. Between 16–20 h post-infection, CteG-2HA mostly associated with the 
Golgi; however, CteG-2HA also appeared at the host cell plasma membrane, and at 30 or 40 h post-
infection this was its predominant localization. This change in the main localization of CteG-2HA was 
independent of intact microfilaments or microtubules. Ectopic expression of different regions of CteG 
(656 amino acid residues) in uninfected cells revealed that its first 100 residues contain a Golgi targeting 
region. Although a C. trachomatis cteG mutant did not display a defect in intracellular multiplication, 
CteG induced a vacuolar protein sorting defect when expressed in Saccharomyces cerevisiae. This 
suggested that CteG might function by subverting host cell vesicular transport.
Chlamydia trachomatis serovars are obligate intracellular bacterial pathogens usually causing ocular and geni-
tal infections that affect millions of people worldwide and can lead to blindness and sterility. Serovars A-C are 
normally associated with trachoma1, while serovars D-K are the most common cause of sexually transmitted 
bacterial infections2. The less common serovars L1–L3 cause lymphogranuloma venereum (LGV), an invasive 
infection2. The Chlamydia genus includes other species pathogenic for humans (C. pneumoniae and C. psittaci) 
and other animals (C. abortus, C. avium, C. caviae, C. felis, C. gallinacea, C. muridarum, C. pecorum, C. psittaci, 
and C. suis)3.
Chlamydia are characterized by a developmental cycle involving an infectious but non-replicative form, the 
elementary body (EB), and a non-infectious but replicative form, the reticulate body (RB). Adherence of extracel-
lular EBs to host cells leads to invasion and formation of a membrane-bound vacuolar compartment (known as 
the inclusion) where Chlamydia resides, develops and grows intracellularly4. As with many other Gram-negative 
bacteria5, the capacity of Chlamydia to subvert host cells largely relies on a type III secretion (T3S) system medi-
ating the transport of effector proteins into host cells6. In general, the biological function of T3S effectors depends 
on their biochemical activity, timing of delivery and specific subcellular targeting in host cells, and is coordinated 
with the action of other effectors injected by the same bacterium7,8. In Chlamydia, T3S effectors include the Inc 
proteins, characterized by a bilobed hydrophobic motif mediating their insertion into the inclusion membrane9,10. 
The identification of Chlamydia effectors without the bilobed hydrophobic motif is normally more challeng-
ing because their primary structure normally lacks other obvious distinguishable features. However, several of 
these non-Inc C. trachomatis T3S effectors (e.g., TarP, TepP, CT694/TmeA) have been identified and shown to 
modulate chlamydial invasion and diverse host cell functions4,11–15. There are also Chlamydia effectors, such as 
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deubiquitinating enzymes16,17, which localize within the cytoplasm of host cells and that have not been shown to 
be T3S substrates, as well as chlamydial T3S substrates secreted into the inclusion lumen18,19. Some of the non-Inc 
chlamydial effectors localize at the inclusion membrane17,20–22, at the host cell plasma membrane22, or at the host 
cell nucleus23–25, while others are membrane-associated11,26 or have undefined localization.
In this work, following the identification of candidate chlamydial T3S substrates using Yersinia enterocolitica 
as a heterologous host27,28, we show that the C. trachomatis CT105 protein (CTL0360 in C. trachomatis serovar L2 
strain 434/Bu; L2/434) is delivered into host cells during infection. In infected cells, bacterially-delivered CT105 
initially mainly localized at the Golgi complex and then at the plasma membrane. CT105 is the first Chlamydia 
protein described to localize at the Golgi in infected cells, and we identified a Golgi-targeting region within its 
first 100 amino acid residues. Using Saccharomyces cerevisae as model, we also show that CT105 can modulate 
eukaryotic vesicular trafficking.
Results
CT105-2HA is delivered by C. trachomatis into the cytoplasm of infected cells. To test if the can-
didate chlamydial T3S substrates CT053, CT082, CT105, CT429, and CT84927,28 can be transported by Chlamydia 
into the cytoplasm of host cells, C. trachomatis strain L2/434 was transformed with plasmids encoding these 
proteins with a double hemagglutinin (2HA) epitope tag at their C-termini. Protein production was confirmed by 
immunoblotting of extracts of HeLa cells infected for 40 h with C. trachomatis strains harboring plasmids encod-
ing CT053-2HA (predicted molecular mass of 17 kDa), CT082-2HA (60 kDa), CT105-2HA (68 kDa), CT429-
2HA (39 kDa), or CT849-2HA (18 kDa) (Figs 1A and S1). The strains producing CT053-2HA, CT082-2HA and 
CT105-2HA also showed species migrating on SDS-PAGE at a molecular mass different from the one predicted 
for the full-length proteins (Figs 1A and S1), as previously observed when identical 2HA-tagged versions of the 
proteins were produced in Y. enterocolitica27,28. Overall, these experiments confirmed that the constructed C. 
trachomatis strains expressed the expected 2HA-epitope tagged proteins.
To analyze the subcellular localization of CT053-2HA, CT082-2HA, CT105-2HA, CT429-2HA, and CT849-2HA, 
HeLa cells were infected for 20 or 40 h with C. trachomatis L2/434-derived strains bearing the corresponding encod-
ing plasmids and then analyzed by immunofluorescence microscopy. At 20 p.i. (Fig. 1B) or 40 h p.i. (Supplementary 
Fig. S2), CT053-2HA, CT082-2HA, CT429-2HA, and CT849-2HA were only detected within the inclusion 
and/or colocalizing with the C. trachomatis major outer membrane protein (MOMP) signal (Figs 1B and S2). 
Figure 1. The chlamydial candidate T3S effector CT105 is delivered by C. trachomatis into the cytoplasm of 
infected cells. HeLa cells were either left uninfected (UI) or infected by C. trachomatis L2/434-derived strains 
harboring the indicated plasmids, encoding candidate T3S effectors (CT053, CT429, CT105, CT082, CT849) 
with a 2HA epitope tag at their C-termini. (A) At 40 h p.i., whole cell extracts were analyzed by immunoblotting 
with antibodies against HA, MOMP (bacterial loading control) and α-tubulin (HeLa loading control) using 
SuperSignal West Pico detection kit (Thermo Fisher Scientific), or SuperSignal West Femto detection kit 
(Thermo Fisher Scientific) for CT849-2HA. Asterisks indicate the bands likely corresponding to the full-length 
proteins. Whole immunoblots are presented in Supplementary Fig. S1. (B) At 20 h p.i., cells were fixed with 
4% (w/v) PFA, stained with DAPI (blue), immunolabeled with antibodies against HA (red) and C. trachomatis 
MOMP (green), and appropriate fluorophore-conjugated secondary antibodies, and imaged by fluorescence 
microscopy. Scale bars, 10 µm.
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In contrast, CT105-2HA was detected outside of the inclusion, indicating it is bacterially-delivered into the cyto-
plasm of infected host cells (Figs 1B and S2).
Full-length orthologues of CT105 are only present in C. muridarum and C. suis, and ct105 
expression is mostly restricted to C. trachomatis LGV strains. CT105 is a protein of 656 amino 
acid residues whose sequence does not show significant similarity to other proteins except for potential ortho-
logues in other Chlamydia spp. However, full-length orthologues of CT105 were only found in C. muridarum 
and C. suis (Supplementary Table S1). In C. suis and in other Chlamydia spp. different open reading frames might 
encode proteins with some identity (between 30–22%) to only some parts of the amino acid sequence of CT105 
(Supplementary Table S1). As previously noted29, analysis of the mRNA levels of ct105 by reverse transcrip-
tion quantitative PCR (RT-qPCR) in different C. trachomatis strains revealed that the gene is only significantly 
expressed in LGV strains (serovars L1–L3) (Supplementary Fig. S3). Furthermore, also as previously noted29, con-
sidering the promoter region of ct105 based on the transcription start site identified in C. trachomatis LGV strain 
L2b/UCH-1/proctitis30, C. trachomatis non-LGV strains (serovars A-K) lack 74 nucleotides upstream from the 
putative −10 region recognized by C. trachomatis σ66 (Supplementary Fig. S4). It has also been previously shown 
that ct105 is a pseudogene in C. trachomatis ocular strains (serovars A-C)31. Therefore, among C. trachomatis 
serovars, active CT105 is mostly produced by LGV strains.
Characterization of C. trachomatis expressing plasmid-encoded CT105-2HA. The L2/434 strain 
harboring pCT105-2HA, was then characterized by comparison to the parental strain. The profile of expression 
of ct105 during the developmental cycle of C. trachomatis was similar between the two strains (Supplementary 
Fig. S5). In agreement with previous observations27 (Supplementary Fig. S3), the highest levels of ct105 mRNA 
were detected at 2 h p.i. (Supplementary Fig. S5). Furthermore, at 2 h p.i., the strain harboring pCT105-2HA 
showed a 10-fold increase in the mRNA levels of ct105 relative to the parental strain (Supplementary Fig. S5). 
However, expression of plasmid-encoded CT105-2HA in C. trachomatis had no significant impact on chlamydial 
growth (Supplementary Fig. S5).
In extracts of HeLa cells infected by C. trachomatis L2/434 harboring pCT105-2HA, the 2HA-tagged protein 
could be detected by immunoblotting from 16 to 40 h p.i. (Supplementary Fig. S6). In addition to the band likely 
corresponding to full-length CT105-2HA (68 kDa), several faster migrating species of a lower molecular mass 
were consistently observed between 20 to 40 h p.i. (Supplementary Fig. S6). Similar observations were made 
by immunoblotting of extracts of HeLa cells infected by strain L2/434 harboring a plasmid (pTet-CT105-2HA) 
where production of CT105-2HA is driven by the tetracycline promoter (Ptet) (Supplementary Fig. S6). This 
indicates that plasmid-encoded CT105-2HA is modified and/or degraded as the C. trachomatis developmental 
cycle progresses. Immunoblotting of extracts of HeLa cells infected by L2/434 harboring either pCT105-2HA or 
pTet-CT105-2HA, or of corresponding Chlamydia-enriched extracts, suggested that this modification and/or 
degradation of CT105-2HA occurs within the bacterium (Supplementary Fig. S6).
CT105-2HA localizes at the Golgi complex in C. trachomatis-infected cells. To analyze in further 
detail the localization of CT105-2HA during infection, HeLa cells were infected for different times by C. tra-
chomatis L2/434 harboring pCT105-2HA and then analysed by immunofluorescence microscopy. At 2, 4, and 8 h 
p.i., CT105-2HA could be detected colocalizing with the signal for C. trachomatis Hsp60 (Supplementary Fig. S7), 
which suggested its presence within the bacterial cells. At 16 and 20 h p.i., CT105-2HA was detected outside of 
the inclusion in approximately 37% and 90% of the infected cells, respectively (Supplementary Fig. S7); at 30 
and 40 h p.i., the protein was found outside of the inclusion in all infected cells (Supplementary Fig. S7). While 
at 16, 20, and 30 h p.i. CT105-2HA was detected in the host cell cytoplasm concentrated at one of the sides of the 
inclusion, at 30 h p.i. the protein was also detected at the periphery of the infected cells (Supplementary Fig. S7). 
Furthermore, at 40 h p.i., CT105-2HA was mostly seen at the periphery of the infected cells (Supplementary 
Fig. S7).
The accumulation of CT105-2HA near the inclusion in the cytoplasm of infected cells suggested it could local-
ize at the Golgi complex. This immunofluorescence signal of CT105-2HA also appeared less compact at longer 
times of infection, which was evocative of the Golgi fragmentation seen in C. trachomatis infected-cells32. To 
analyze this, HeLa cells infected by C. trachomatis L2/434 harboring pCT105-2HA were fixed at 16, 20, 30, or 40 h 
p.i. and then analyzed by immunofluorescence microscopy. This revealed that CT105-2HA localized in the Golgi 
region at 16, 20, and 30 h p.i., and that this was much less evident at 40 h p.i. (Fig. 2). There was not a perfect colo-
calization of CT105-2HA with cis-Golgi (GM130) and TGN (TGN46) markers, but the immunofluorescence sig-
nal of CT105-2HA near the inclusion accompanied the dispersion of the Golgi complex during infection (Fig. 2).
To further confirm the association of CT105-2HA with the Golgi, HeLa cells infected by the L2/434 strain 
harboring pCT105-2HA were treated with Brefeldin A (BFA), which induces reversible Golgi fragmenta-
tion33. For this, at 19 h p.i., the infected cells were either incubated for 1 h with BFA or with dimethyl sulfoxide 
(DMSO)-solvent alone and then fixed. In addition, the infected cells were incubated for 1 h with BFA, washed 
out from the BFA, incubated for 1 h and then fixed. Immunofluorescence microscopy revealed that in the 
DMSO-treated infected cells, CT105-2HA accumulated in the Golgi region (Fig. 3), similarly to untreated cells 
infected for 16 or 20 h p.i. (Fig. 2). In cells treated with BFA, the GM130-labeled Golgi fragmented into small vesi-
cles and the immunofluorescence signal of CT105-2HA became dispersed and mostly below the limit of detection 
(Fig. 3). In cells treated with BFA and subsequently washed-out of the drug, both the GM130-labeled Golgi and 
CT105-2HA appeared mostly compact and near the inclusion (Fig. 3). Overall, this showed that CT105-2HA 
associates with the Golgi, at 16–20 h p.i., upon the initial detection of its delivery by C. trachomatis into the cyto-
plasm of infected host cells.
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CT105-2HA localizes at the host cell plasma membrane in C. trachomatis-infected cells. CT105-
2HA was also detected in the periphery of host cells infected by C. trachomatis at 30 or 40 h p.i. (Supplementary Fig. S7), 
which suggested it could localize at the plasma membrane. To analyze this, HeLa cells were infected for 30 and 40 h p.i. 
by C. trachomatis L2/434 harboring CT105-2HA and transfected with a plasmid encoding a palmitoylated/myristoy-
lated peptide from Lyn kinase (Lyn11) [targeting proteins to the plasma membrane34] fused to monomeric EGFP35 
(Lyn11-mEGFP). The cells were then fixed and analyzed by immunofluorescence microscopy. Although CT105-2HA 
did not show a perfect colocalization with either Lyn11-mEGFP or with phalloidin-stained cortical actin (Fig. 4A), this 
showed that at 30 and 40 h p.i., CT105-2HA localizes at the host cell plasma membrane.
The number of infected cells showing CT105-2HA outside of the inclusion and at the Golgi or at the plasma 
membrane were then enumerated (Fig. 4B), which confirmed that in C. trachomatis-infected cells, initial delivery 
of CT105-2HA into the host cell cytoplasm (first detected at 16 h p.i.) results in its accumulation at the Golgi 
region, but as infection progresses this localization of the protein becomes less frequent and CT105-2HA accu-
mulates more often at the periphery of the cell. These observations were recapitulated by the analysis of HeLa cells 
infected by C. trachomatis L2/434 harboring pTet-CT105-2HA (Supplementary Fig. S8). To test if CT105-2HA 
was transported from the Golgi to the plasma membrane in vesicles associated with the microtubule and/or actin 
cytoskeleton, HeLa cells were infected with C. trachomatis harboring pCT105-2HA. At 20 h p.i., when CT105-
2HA mostly localizes at the Golgi region (Fig. 4B), the cells were incubated in the presence of DMSO solvent as a 
control, cytochalasin D or latrunculin B (to inhibit actin polymerization by different mechanisms), or nocodazole 
(to depolymerize microtubules) (Fig. 4C). The cells were then fixed at 30 h p.i., when CT105-2HA mostly localizes 
at the plasma membrane (Fig. 4B), and analyzed by immunofluorescence microscopy. We observed a statistically 
significant difference in the localization of CT105-2HA at the cell periphery when microfilaments were disrupted 
Figure 2. CT105 colocalizes with the Golgi complex in C. trachomatis-infected cells. HeLa cells were infected 
by C. trachomatis L2/434 encoding CT105-2HA. At the indicated times p.i., cells were fixed with 4% (w/v) PFA, 
immunolabeled with antibodies against HA (red), C. trachomatis MOMP (gray), GM130 (green), and TGN46 
(blue), and appropriate fluorophore-conjugated secondary antibodies. In the area delimited by a white square 
(left-side panels) images were zoomed (middle and right-side panels). Immunolabeled cells were examined by 
confocal fluorescence microscopy, and images correspond to single z sections. Scale bars, 10 µm.
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with cytochalasin D (Fig. 4C). However, the small difference relative to DMSO-treated cells, and the absence of 
a significantly different effect upon disruption of the microfilaments with latrunculin B (Fig. 4C), suggests this 
should have no biological significance. Furthermore, disruption of the microtubule network also did not signif-
icantly affect the localization of CT105-2HA at the cell periphery (Fig. 4C). Therefore, CT105-2HA changes its 
predominant localization during infection of host cells by C. trachomatis from the Golgi to the plasma membrane, 
but this is independent of intact host cell microfilaments and microtubules.
The first 100 amino acid residues of CT105 are sufficient to target the protein to the Golgi in 
uninfected mammalian cells. To map the regions of CT105 that could determine its different localiza-
tions within the cytoplasm of mammalian cells, HeLa cells were first transfected for 24 h with plasmids encoding 
full length CT105 fused to the C- or N-termini of monomeric EGFP (mEGFP-CT105FL and CT105FL-mEGFP, 
respectively) or with C-terminal 2HA-epitope tag. Immunoblotting of whole cell extracts confirmed the produc-
tion of proteins of the predicted molecular mass (Supplementary Fig. S9). Furthermore, fluorescence microscopy 
showed that mEGFP-CT105FL, CT105FL-mEGFP, or CT105-2HA localized predominantly at the periphery of the 
cell (Supplementary Fig. S9), recapitulating a main localization of CT105-2HA in cells infected by C. trachoma-
tis for 30 h or 40 h (Fig. 4B). Next, HeLa cells were transfected with plasmids encoding mEGFP-CT105FL (pre-
dicted molecular mass of 96 kDa) and different truncated versions of CT105 fused to the C-terminus of mEGFP: 
mEGFP-CT1051–100 (38 kDa), mEGFP-CT105Δ100 (86 kDa) mEGFP-CT1051–320 (60 kDa), mEGFP-CT105Δ320 
(65 kDa), or mEGFP-CT105Δ100–320 (74 kDa) (Fig. 5A). As the primary structure of CT105 revealed no predicted 
transmembrane domains or other obvious targeting motifs, these truncations were designed only considering the 
predicted secondary structure of CT105 [deduced using JPred436]. Immunoblotting of whole cell extracts con-
firmed the production of mEGFP-CT105FL, mEGFP-CT1051–100, mEGFP-CT105Δ100, or mEGFP-CT105Δ100–320 
proteins of the predicted molecular mass (Fig. 5B). The production of mEGFP-CT1051–320 and mEGFP-CT105Δ320 
proteins of the predicted molecular mass was not detected (Fig. 5B), and they were not further analyzed. HeLa 
cells ectopically expressing mEGFP-CT105FL, mEGFP-CT1051–100, mEGFP-CT105Δ100, or mEGFP-CT105Δ100–320 
were fixed and analyzed by immunofluorescence microscopy for localization of the fusion protein at the cell 
periphery (as an indication of plasma membrane localization) and at the Golgi. The mEGFP-CT105FL protein 
localized only at the cell periphery in 68 ± 8% of the transfected cells, and only at the Golgi in 7 ± 2% of the 
transfected cells (Fig. 5C,D). However, the fluorescent signal was generally weak in the Golgi region (Fig. 5C). 
Strikingly, mEGFP-CT1051–100 localized at the Golgi region in almost all transfected cells (98 ± 1%) and was not 
detected at the cell periphery (Fig. 5C,D). In contrast, mEGFP-CT105Δ100 was mostly cytosolic and was never 
Figure 3. CT105 associates with the Golgi complex in C. trachomatis-infected cells. HeLa cells were infected 
by C. trachomatis L2/434 encoding CT105-2HA. At 19 h p.i., cells were treated for 1 h with DMSO or 1 µg/ml 
BFA. Then, the cells were either fixed with 4% (w/v) PFA (upper and middle panels) or washed with complete 
medium lacking BFA and incubated for an additional 1 h and then fixed with 4% (w/v) PFA (lower panels). 
Fixed cells were immunolabeled with antibodies against HA (red), C. trachomatis MOMP (gray), and GM130 
(green), and appropriate fluorophore-conjugated secondary antibodies. In the area delimited by a white square 
(left-side panels) images were zoomed (right-side panels). All immunolabeled cells were examined by confocal 
fluorescence microscopy, and images correspond to single z sections. Scale bars, 10 µm.
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seen at the Golgi complex and only seldom (2 ± 0%) at the cell periphery (Fig. 5C,D). mEGFP-CT105Δ100–320 
showed a punctate/vesicular appearance with no marked localization at the Golgi (4 ± 1%) or cell periphery 
(18 ± 1%), particularly when compared with mEGFP-CT105Δ100 or mEGFP-CT105FL (Fig. 5C,D).
To confirm the association of mEGFP-CT1051–100 with the Golgi, and to analyze its localization within the 
Golgi complex, HeLa cells that had been transfected for 24 h were either incubated for 1 h with BFA or DMSO sol-
vent, and then fixed. In addition, the transfected cells were incubated for 1 h with BFA, washed out from the BFA, 
incubated for 1 h, and fixed. Immunofluorescence microscopy revealed that in the control DMSO-treated cells, 
mEGFP-CT1051–100 localized at the Golgi region, and showed significant colocalization with TGN46 (Fig. 5E) but 
not with GM130 (Supplementary Fig. S9). BFA-induced Golgi fragmentation resulted in near complete disper-
sion of the fluorescence signal of mEGFP-CT1051–100 (Figs 5E and S9). However, BFA-induced Golgi fragmenta-
tion followed by BFA wash out revealed again a compact Golgi complex and mEGFP-CT1051–100 in that region 
mostly colocalizing with TGN46 (Fig. 5E) but not with GM130 (Supplementary Fig. S9).
Figure 4. CT105 localizes at plasma membrane in C. trachomatis-infected cells. HeLa cells were infected by C. 
trachomatis L2/434 encoding pCT105-2HA. (A) Cells were also transfected with a plasmid encoding the plasma 
membrane marker Lyn11-mEGFP (green). At 30 or 40 h p.i., cells were fixed with 4% (w/v) PFA, stained with 
phalloidin (blue), and immunolabeled with antibodies against HA (red) and C. trachomatis MOMP (gray), 
and appropriate fluorophore-conjugated secondary antibodies. Cells were imaged by confocal fluorescence 
microscopy and images correspond to single z sections. In the area delimited by a white square (left-side panels) 
images were zoomed (right-side panels). Scale bars, 10 µm. (B) Infected cells were fixed with 4% (w/v) PFA 
at 16, 20, 30 or 40 h p.i. and immunolabeled with antibodies against HA, C. trachomatis MOMP, and GM130, 
and appropriate fluorophore-conjugated secondary antibodies. Fluorescence microscopy was then used to 
enumerate cells showing CT105-2HA only at the Golgi, only at the plasma membrane (PM), or both at the 
Golgi and at the plasma membrane (Golgi + PM). Data are mean ± standard error of the mean (SEM) of three 
independent experiments (n ≥ 25). (C) At 20 h p.i., infected cells were treated with DMSO, 1 µg/ml nocodazole, 
2 µM cytochalasin D or 500 nM latrunculin B. At 30 h p.i., the cells were fixed with 4% (w/v) PFA and labeled 
with immunolabeled with antibodies against HA, C. trachomatis MOMP, and appropriate fluorophore-
conjugated secondary antibodies. Fluorescence microscopy was used to enumerate cells showing CT105-
2HA at the periphery of the cell/plasma membrane. Data are mean ± SEM of three independent experiments 
(n = 50). P-values were obtained by one-way ANOVA and Bonferroni post-test analyses; *statistical significant 
(P < 0.05); ns, not significant.
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In summary, ectopically expressed full-length CT105 (mEGFP-CT105FL, CT105FL-mEGFP, and CT105-2HA) 
localized at the cell periphery and mEGFP-CT1051–100 at the Golgi, generally recapitulating the localization of 
CT105-2HA in infected cells. As mEGFP-CT1051–100 showed a striking association with the TGN in uninfected 
cells, this indicated that the first 100 amino acids of CT105 contain a Golgi-targeting region.
Figure 5. The first 100 amino acids of CT105 contain a Golgi-targeting region. HeLa cells were transfected for 
24 h with plasmids encoding monomeric EGFP (mEGFP) or different regions of CT105 fused to the C-terminus 
of mEGFP (CT105-mEGFP proteins), as indicated. (A) Schematic representation of the mEGFP-CT105 
proteins expressed and analyzed. (B) Total extracts of transfected cells were analyzed by immunoblotting 
with antibodies against GFP and α-tubulin (HeLa loading control) using SuperSignal West Pico detection 
kit (Thermo Fisher Scientific). (C) Transfected cells were fixed with 4% (w/v) PFA, labeled with antibodies 
against TGN46 (red), and the appropriate fluorophore-conjugated secondary antibody, and imaged by confocal 
fluorescence microscopy. Images correspond to single z sections. Scale bars, 10 µm. (D) Cells immunolabeled 
as described in C were enumerated by fluorescence microscopy for localization of mEGFP-CT105 only at the 
Golgi, only at the plasma membrane (PM), or both at the Golgi and plasma membrane (Golgi + PM). Data 
are mean ± standard error of the mean of three independent experiments (n = 100). (E) Cells were treated 
for 1 h with DMSO or 1 µg/ml BFA. Then, the cells were either fixed with 4% (w/v) PFA (upper and middle 
panels) or washed with complete medium lacking BFA and incubated for an additional 1 h and then fixed with 
4% (w/v) PFA (lower panels). The fixed cells were immunolabeled with antibodies against TGN46 (red), and 
the appropriate fluorophore-conjugated secondary antibody, and examined by confocal immunofluorescence 
microscopy. Images correspond to single z sections. In the area delimited by a white square (left-side panels) 
images were zoomed (right-side panels). Scale bars, 10 µm.
8Scientific RepoRts |          (2019) 9:6133  | https://doi.org/10.1038/s41598-019-42647-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
CT105 is not essential for intracellular multiplication of C. trachomatis in infected tissue cul-
ture cells. To examine the importance of CT105 during infection of tissue culture cells by C. trachomatis, a 
L2/434-derived strain where the ct105 gene was inactivated by an insertion between nucleotides 261 and 262 of 
a modified group II intron containing a spectinomycin-resistance gene (aadA) was constructed (Supplementary 
Fig. S10). To confirm that insertion of the intron prevented production of CT105, in the absence of a specific 
anti-CT105 antibody, a C. trachomatis strain harboring a plasmid (pCT105::aadA-2HA) was constructed with 
the ct105::aadA mutant allele and the sequence encoding 2HA fused to the 3′ end of ct105. HeLa cells were then 
infected for 40 h with C. trachomatis L2/434 harboring either pCT105-2HA or pCT105::aadA-2HA and analysed 
by immunoblotting. This confirmed that intron insertion within ct105-2HA prevented production of a protein 
detectable with anti-HA antibodies (Fig. 6A).
The intracellular growth of C. trachomatis L2/434 (parental strain), ct105::aadA mutant, and ct105::aadA 
mutant harboring CT105-2HA (complemented strain) was then monitored by quantifying the production of 
infectious progeny during the chlamydial developmental cycle. Based on this, no significant differences between 
the three strains were detected (Fig. 6B). However, when HeLa cells infected by the same strains for 24 h were 
fixed and analysed by immunofluorescence microscopy, this revealed that the inclusion size was smaller in the 
mutant and complemented strains by comparison to the parental strain (Fig. 6C,D). Because this difference in 
inclusion size between the mutant and the parental strain was also observed in the complemented strain, the 
defect is likely not due to the absence of CT105. Probably, intron insertion within ct105 might have caused a polar 
effect in the neighbouring genes. In summary, this showed that CT105 is not required for C. trachomatis growth 
in tissue culture cells. In addition, considering the localization of CteG at the Golgi, we analysed if its morphol-
ogy was altered in HeLa cells infected by the ct105::aadA mutant, by comparison to cells infected by the parental 
L2/434 strain. However, significant differences in Golgi morphology were not detected (Supplementary Fig. S11).
CT105 induces a vacuolar protein sorting defect when ectopically expressed in S. cerevisiae. 
Given the localization of CT105 at the Golgi and plasma membrane in both infected and transfected mammalian 
cells, we hypothesized that the protein could interfere with eukaryotic vesicular trafficking. To test this, we asked 
if CT105 could cause a vacuolar protein sorting (VPS) defect in S. cerevisiae37, a eukaryotic model organism 
that has been often used to study bacterial effector proteins38. The VPS assay consists in a yeast reporter strain 
NSY01 (Supplementary Table S2) that produces a hybrid protein composed of carboxypeptidase Y and Invertase 
(CPY-Inv), which normally travels to the yeast vacuole but goes to the cell surface if trafficking is disrupted. As 
strain NSY01 does not produce endogenous Invertase, an enzyme that hydrolyzes sucrose into glucose and fruc-
tose, normal (Vps+) or aberrant (Vps−) trafficking of CPY-Inv can be scored by using an agar overlay solution 
indicating glucose production at the cell surface by formation of a brown precipitate (Vps+, white colonies; Vps−, 
brown colonies)37.
Strain NSY01 was transformed with yeast expression plasmids encoding either CT105 fused to the N-terminus 
or C-terminus of GFP (CT105-GFP or GFP-CT105, respectively) under the control of a galactose inducible pro-
moter (Fig. 7A). The first controls used were a NSY01 derivative strain that expressed only GFP (Fig. 7A), which 
leads to a Vps+ phenotype39, and NSY01 derivative strains expressing a dominant-negative form of the yeast 
ATPase Vps4 (Vps4E233Q)40 or the Legionella pneumophila effector protein VipA (Fig. 7A), both known to cause a 
Vps− phenotype37,39. In the qualitative colorimetric enzymatic assay in solid media, it was consistently observed 
that GFP-CT105 or CT105-GFP induced a Vps− phenotype (Fig. 7B). In addition, quantitative analyses in liq-
uid media were performed and the amounts of secreted and total invertase were assessed for each strain. In 
this assay, both GFP-CT105 and CT105-GFP caused an increase in the levels of secreted invertase (relative to 
those of the control strain expressing GFP), but the difference was only statistically significant for GFP-CT105 
(Fig. 7C). The C-terminal half of CT105 (amino acid residues 351 to 656), but not its N-terminal part (amino 
acid residues 1-443), was sufficient to induce a VPS defect in S. cerevisiae (Supplementary Fig. S12), indicat-
ing that the VPS-inhibitory activity of CT105 depends on its C-terminal region. Moreover, production in yeast 
of a fusion to GFP of another C. trachomatis type III secreted protein (CT14227) did not induce a VPS defect 
(Supplementary Fig. S12). Finally, production of GFP-CT105 or CT105-GFP caused no toxicity in S. cerevisiae 
NSY01 (Supplementary Fig. S12), indicating that the induction of the VPS defect by CT105 was not a conse-
quence of an overall impact on yeast physiology. Thus, ectopic expression of CT105 in S. cerevisiae disrupted 
vesicular trafficking to the yeast vacuole.
Discussion
We found that the C. trachomatis CT105 protein is delivered into the cytoplasm of infected host cells. At distinct 
times of the chlamydial developmental cycle, CT105 accumulates at the Golgi complex (16–30 h p.i.) and/or at the 
host cell plasma membrane (30–40 h p.i.). Because CT105 can be secreted by the T3S system of Y. enterocolitica27 
and can interfere with vesicular trafficking in S. cerevisiae (Figs 7 and S12), this indicates that CT105 is a newly 
identified C. trachomatis T3S effector. However, thus far, we have no direct evidence for the ability of CT105 to 
interfere with vesicular trafficking in infected human cells and this must be analyzed directly in future studies. 
Overall, this work expands the portfolio of known chlamydial effector proteins and reveals the first Chlamydia 
protein that associates with the Golgi complex. Moreover, it illustrates that a single C. trachomatis effector can 
have distinct subcellular localizations, and possibly different functions, during the chlamydial developmental 
cycle. Such dual localization during infection as a likely means to diversify effector function is evocative of the 
Salmonella SopB effector, which initially localizes at the host cell membrane to mediate bacterial invasion but is 
then redirected to the Salmonella-containing vacuole to modulate bacterial intracellular growth41.
In addition to CT105, the C. trachomatis effector CT867, a deubiquitinase enzyme known as ChlaDub216 or 
Cdu217, has been detected at the inclusion membrane and at the host cell plasma membrane at distinct times of 
infection22. Such localization of CT105 and CT867/ChlaDub2/Cdu2 later in infection might indicate a function 
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in host cell exit. It is unknown how CT105 and CT867/ChlaDub2/Cdu2 are differentially directed to different host 
cell localizations. In the case of CT105, it is unlikely that vesicular trafficking is involved as disruption of micro-
filaments and microtubules did not affect its localization at the plasma membrane in infected cells. We envision 
that host cytosolic CT105 is specifically directed to different subcellular localizations by covalent modifications 
it might be subjected to and/or by changes in the lipid and/or protein composition of host cellular membranes.
Ectopic expression of CT105 in yeast inhibited protein transport to the vacuole. While it remains to be directly 
tested, this observation suggested a potential capacity of CT105 to interfere with vesicular trafficking in infected 
cells. An appealing possibility for the function of CT105 would be that it contributes to nutrient acquisition by 
the inclusion and/or avoidance of fusion with hydrolytic compartments. However, the C. trachomatis ct105::aadA 
mutant did not reveal an obvious intracellular growth defect, which is not uncommon amongst C. trachomatis 
effector gene mutants characterized thus far11,42,43 and might reflect redundancy in effector function or inexist-
ence of adequate infection models7. Furthermore, a putative activity of CT105 on vesicular trafficking in infected 
Figure 6. A C. trachomatis ct105::aadA insertional mutant is not defective for intracellular growth in tissue 
culture cells. (A,C) trachomatis ct105::aadA insertional mutant was generated in the strain L2/434 by the 
targeted insertion of a modified group II intron carrying a spectinomycin-resistance gene. (A) Hela cells 
were infected by C. trachomatis L2/434 harboring a plasmid encoding CT105-2HA or by an identical plasmid 
carrying a ct105::aadA-2HA mutant allele. Whole cell extracts were analyzed by immunoblotting with 
antibodies against HA, C. trachomatis Hsp60 (bacterial loading control) and α-tubulin (HeLa loading control) 
using SuperSignal West Pico detection kit (Thermo Fisher Scientific) for Hsp60 and α-tubulin, or SuperSignal 
West Femto detection kit (Thermo Fisher Scientific) for HA. (B) HeLa cells were infected for 24, 30, or 40 h 
by C. trachomatis L2/434 or ct105::aadA mutant at the multiplicity of infection of 1, and recoverable inclusion 
forming units (IFUs) were enumerated. Data ± standard error of the mean of 3 independent experiments. For 
each time-point, P-values were obtained by one-way ANOVA and Dunnett post-test analyses relative to the 
L2/434 parental strain; ns, not significant (P ≥ 0.05). (C) Hela cells were infected for 24 h by C. trachomatis 
L2/434, ct105::aadA mutant, or ct105:aadA harboring pCT105-2HA. Cells were fixed with methanol, labeled 
with goat anti-C. trachomatis FITC-conjugated antibody and imaged by fluorescence microscopy. Scale bars, 
10 µm. (D) The inclusion area was measured (from images as those depicted in C) for 50 particles randomly 
chosen from independent images using Fiji software. P-values were obtained by one-way ANOVA and Dunnett 
post-test analyses; *statistical significant (P < 0.05).
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cells could also affect cytokine secretion44 or immune signaling45, which would not have an impact on chlamydial 
intracellular growth in tissue culture cells. Although the ct105 mutant revealed smaller inclusions relative to the 
parental strain (suggesting a possible defect in vacuolar membrane expansion), this could not be restored by 
reintroduction of ct105 in trans. The exact reasons for this need to be further analyzed, but the inability to com-
plement intracellular growth-like phenotypes in intron insertional mutants of C. trachomatis was also recently 
described for ct101/mrcA46, while other specific phenotypes of this mutant strain could be complemented46.
The precise spatial and temporal subcellular targeting of bacterial effector proteins during infection is an 
essential feature of their function47. In other bacterial pathogens at least three other effector proteins have been 
shown to localize at the Golgi in infected host cells. These are EspI/NleA from Escherichia coli48, GobX from 
L. pneumophila49, and SteD from Salmonella enterica50. EspI/NleA interferes with coatomer protein II complex 
function, inhibits host cell protein secretion51, and disrupts intestinal tight junctions52. In addition, EspI/NleA 
inhibits NLRP3 inflammasome activation53. GobX displays E3 ubiquitin ligase activity, but how this promotes 
L. pneumophila infection is unknown49. Finally, SteD interferes with the activity of a host E3 ubiquitin ligase, 
leading to a reduction of surface-localized major histocompatibility complex class II molecules and suppression 
of T cell activation50. This illustrates that no specific function can be predicted for CT105 based on its localization 
at the Golgi.
The first 100 amino acid residues of CT105 are sufficient for Golgi localization when the protein is ectopically 
expressed in Hela cells. However, this region does not display obvious motifs found in other relevant eukaryotic 
or bacterial proteins, and the exact molecular determinants of the Golgi localization of CT105 remain to be 
identified. Other relevant questions are whether the same determinants are responsible for Golgi localization 
in infected cells and which characteristics of the full-length CT105 protein enable its targeting to the plasma 
membrane. Other effector proteins that localize at the Golgi in infected cells use distinct mechanisms directing 
them to the organelle49,50,54,55. In the case of EspI/NleA, Golgi targeting is partially mediated by a Postsynaptic 
Density95/Disc Large/Zonula Occludens-1 (PDZ) domain on its C-terminus54. CT105 also possesses a putative 
PDZ domain56, but the relevant residues are not involved in its subcellular localization after ectopic expression in 
mammalian cells (data not shown).
CT105 displays a striking variability within C. trachomatis serovars, revealing LGV-specific genetic and tran-
scriptomic traits. This suggests that CT105 could have a specific function related with the unique characteristics 
of infections by these strains, which, unlike ocular and urogenital C. trachomatis strains, can infect mononuclear 
phagocytes and disseminate into regional lymph nodes29,57. It also indicates that features of the infection by LGV 
strains should be an evolutionary pressure to maintain an active ct105 gene. Furthermore, among Chlamydia 
Figure 7. CT105 induces a vacuolar protein sorting defect in S. cerevisiae. S. cerevisiae reporter strain NSY01 
producing CPY-invertase was transformed with plasmids encoding GFP (pKS84), VipA-GFP, GFP-CT105, 
or CT105-GFP, where their expression can be induced by galactose. A NSY01 derivative strain encoding 
a dominant-negative form of the yeast ATPase Vps4 (Vps4E233Q) was also used. Yeast strains are listed in 
Supplementary Table S2. (A) Whole cell extracts of S. cerevisiae NSY01 producing the indicated proteins 
were analyzed by immunoblotting with antibodies against GFP and PGK1 (yeast loading control), using 
SuperSignal West Pico detection kit (Thermo Fisher Scientific). (B) S. cerevisiae NSY01 strains encoding the 
indicated proteins were grown in solid medium in the presence of galactose (inducing conditions, +GAL) or 
in the presence of fructose (non-inducing conditions; +FRU). The vacuolar protein sorting (VPS) phenotype 
was analyzed using a sucrose overlay to assess activity of secreted invertase. A vacuolar protein sorting defect 
(VPS−) leads to the formation of a brown precipitate. (C) S. cerevisiae NSY01 strains encoding the indicated 
proteins were grown in liquid medium in the presence of galactose (inducing conditions) and the relative 
activity of secreted invertase was quantified (see Experimental Procedures). Data are mean ± standard error of 
the mean of five independent experiments. P-values were obtained by one-way ANOVA and Dunnett post-test 
analyses relative to GFP (0% of relative secreted invertase; not shown); *statistical significant (P < 0.05); ns, not 
significant.
1 1Scientific RepoRts |          (2019) 9:6133  | https://doi.org/10.1038/s41598-019-42647-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
species, full-length orthologues of CT105 are only present in C. muridarum and C. suis, consistent with the fact 
that these species are the closer relatives of C. trachomatis3.
In summary, we identified CT105 as a T3S effector of C. trachomatis that localizes to the Golgi and plasma 
membrane in infected cells, and which can disrupt trafficking to the S. cerevisiae vacuole. Because CT105 is the 
first Chlamydia effector shown to associate with the Golgi complex, we propose to name it CteG (for C. trachoma-
tis effector associated with the Golgi). The identification of CteG also leaves many questions to be addressed 
related to its function, subcellular targeting mechanisms, diversity, and specificity within C. trachomatis and 
among Chlamydia species.
Materials and Methods
Plasmids, primers, and DNA manipulation. The plasmids used in this work, their main characteristics 
and construction details, are described in Supplementary Table S3. The DNA primers used in their construction 
are listed in Supplementary Table S4. Plasmids were constructed and purified using standard molecular biology 
procedures. The accuracy of the nucleotide sequence of all the inserts in the constructed plasmids was confirmed 
by DNA sequencing. The backbone plasmids used in this work were: pSVP24719, a derivative of p2TK2-SW258, 
was used to generate C. trachomatis expression plasmids encoding proteins with a 2HA at their C-termini; pmEG-
FP-N1 and pmEGFP-C1 [both constructed from pEGFP-N1 (Clontech) and pEGFP-C1 (Clontech), respectively, 
where the gene encoding EGFP was replaced by a gene encoding mEGFP from pLAMP1-mGFP35], and pEF6/
Myc-His A (Thermo Fisher Scientific), were used to generate mammalian transfection plasmids; pYES2-GFP59 
and pKS8460, were used to generate yeast expression plasmids encoding fusions to the C- or N-terminus of GFP, 
respectively. Furthermore, pBOMB4-Tet-mCherry61 and Lyn11-FRB-mCherry62 were used to amplify the Ptet and 
the nucleotide sequence encoding the Lyn11 peptide, respectively.
Cells lines and transient transfection. HeLa 229 and Vero cells (from the European Collection of Cell 
Culture; ECACC) were maintained in high-glucose Dulbecco’s modified Eagle Medium (DMEM; Thermo Fisher 
Scientific) supplemented with heat-inactivated 10% (v/v) fetal bovine serum (FBS; Thermo Fisher Scientific) at 
37 °C in a humidified atmosphere of 5% (v/v) CO2. Cells were checked for Mycoplasma by conventional PCR 
either using the Venor GeM Advance kit (Minerva Biolabs) or as described63. HeLa cells were transfected by using 
the jetPEI reagent (Polyplus-Transfection) according to the instructions of the manufacturer.
Bacterial strains and growth conditions. E. coli TOP10 (Thermo Fisher Scientific) or NEB 10β (New 
England Biolabs) were used for construction and purification of plasmids, and E. coli ER2925 (New England 
Biolabs) was used to amplify and purify plasmids for transformation of C. trachomatis. E. coli strains were rou-
tinely grown in liquid or solid lysogeny broth (LB) medium (NZYTech) with the appropriate antibiotics and 
supplements at 37 °C.
C. trachomatis prototype strains B/Har36, C/TW3, E/Bour, L2/434, and L3/404 (from ATCC) and clinical 
strains F/CS465-95 and L2b/CS19-08 (from the collection of the Portuguese National Institute of Health) were 
propagated in HeLa 229 cells using standard techniques64. Transformation of C. trachomatis was done essentially 
as described by Agaisse and Derré58. The optimal antibiotic concentrations to select transformants were 1 U/ml of 
penicillin G, or 250 µg/ml of spectinomycin. Once established, the transformed strains were cultured in the pres-
ence of 10 U/ml of penicillin, or 500 µg/ml of spectinomycin, and plaque purified using Vero cells, as described65. 
Infection of mammalian cells by C. trachomatis and quantification of infection progeny was done as previously 
described19. Infected cells were harvested at the indicated times post-infection and analyzed by immunoblotting 
or immunofluorescence microscopy.
Construction of a C. trachomatis ct105::aadA mutant strain. A C. trachomatis ct105::aadA 
mutant was generated using group II intron-based insertional mutagenesis, as previously described66,67. 
Briefly, intron-insertion sites in the C. trachomatis L2/434 ctl0360 gene (orthologue of ct105 in C. trachoma-
tis strain D/UW3) were identified using the TargeTron algorithm (Sigma). Then, the intron in pDFTT3aadA67 
(Supplementary Table S2) was retargeted for ctl0360 using standard molecular biology procedures and the DNA 
primers listed in Supplementary Table S4. The ctl0360 mutator plasmid (pDFTT296; Supplementary Table S3) 
was then used to transform C. trachomatis L2/434.
Yeast strains and invertase assays. S. cerevisiae strains (Supplementary Table S2) used in this work were 
grown as previously described37,39. For the invertase assays, S. cerevisiae expressing GFP fusion proteins were 
grown in plates with yeast nitrogen base uracil dropout (YNB-Ura) supplemented with 2% (w/v) fructose for 3 
days, at 25 °C. Cells were then streaked on YNB-Ura with 2% (w/v) fructose (non-inducing media) or 2% (w/v) 
galactose (inducing media) and grown for 3 days at 25 °C. Assays for qualitative and quantitative detection of 
invertase enzymatic activity were performed as described37,68. Relative secreted invertase was normalized by set-
ting GFP as the minimum value and Vps4E233Q as the maximum value.
Antibodies, fluorescent dyes, and drug treatments. The list of antibodies and fluorescent dyes used 
is described in Supplementary Materials and Methods. To induce Golgi fragmentation, HeLa 229 cells were incu-
bated with 1 µg/ml of BFA (Sigma; stock solution at 5 mg/ml in DMSO) for 1 h and then either fixed immediately 
or washed with medium without BFA and incubated for 1 h before fixation. To disrupt microtubules, HeLa 229 
cells were incubated in the presence of 1 µg/ml nocodazole (stock solution at 5 mg/ml in DMSO; Sigma). To 
disrupt the actin cytoskeleton, C. trachomatis-infected cells were incubated in the presence of 2 µM cytochalasin 
D (stock solution at 5 mg/ml in DMSO; Sigma) or 500 nM latrunculin B (stock solution at 1 mg/ml in DMSO; 
Sigma) in serum-free DMEM.
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Immunoblotting. To harvest infected or transfected HeLa cells, they were washed once with 
phosphate-buffered saline (PBS) and then detached with TrypLE Express (Thermo Fisher Scientific) by incuba-
tion during 5 min at 37 °C in a 5% [v/v] CO2 atmosphere. The cells were then collected, pelleted by a brief centrif-
ugation, washed 2 times with ice-cold PBS, and stored as a pellet at −20 °C until use. Prior to SDS-PAGE, the cells 
were thawed and resuspended in an appropriate volume of SDS-PAGE loading buffer. The proteins were further 
denatured by an incubation of 5 min at 100 °C, followed by addition of benzonase (Novagen) to destroy DNA and 
reduce the viscosity of the samples.
To prepare Chlamydia-enriched extracts, the infected HeLa cells were lysed by osmotic shock (15 min in sterile H2O). 
Lysates were centrifuged at 170 × g for 10 min at 4 °C. The supernatants were then centrifuged at 24,000 × g  
for 10 min at 4 °C and resulting pellets washed 2 times with ice-cold PBS. The bacteria-enriched pellets were 
resuspended in an appropriate volume of SDS-PAGE loading buffer and the proteins were further denatured by 
an incubation of 5 min at 100 °C.
To prepare yeast extracts, cells were grown for 3 days at 30 °C in YNB-Ura plates supplemented with 2% (w/v) 
fructose and then streaked into YNB-Ura supplemented with 2% (w/v) galactose. Cells corresponding to an opti-
cal density at 600 nm (OD600) of 2.5 were used for immunoblotting.
Samples were separated by 12% (v/v) SDS-PAGE and transferred onto 0.2 μm nitrocellulose membranes 
(Bio-Rad) using Trans-Blot Turbo Transfer System (BioRad). Immunoblot detection was done with SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) or SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Fisher Scientific) (as indicated in figure legends) and exposure to Amersham 
Hyperfilm ECL (GE Healthcare).
Immunofluorescence microscopy. Infected HeLa cells were fixed either in PBS containing 4% (w/v) par-
aformaldehyde (PFA) for 10 min at room temperature or in methanol (−20 °C) for 10 min, as indicated in figure 
legends. For immunostaining, the antibodies were diluted in PBS containing 10% (v/v) horse serum (when fixa-
tion was done with PFA, 0.1% (v/v) Triton X-100 was added to allow permeabilization of cells). After immunola-
belling, the cells were consecutively washed with PBS and H2O. The coverslips were assembled using Aqua-poly/
Mount (Polysciences) on microscopy glass slides, and the cells were examined by conventional fluorescence 
microscopy or by confocal microscopy. Images were processed and assembled using Fiji software69. Analysis of 
Golgi redistribution around the C. trachomatis inclusion was performed as previously described70.
RT-qPCR. To quantify the mRNA levels of ct105 during the developmental cycle of C. trachomatis strains B/
Har36, C/TW3, E/Bour, F/CS465-95, L2/434, L2b/CS19-08 and L3/404, RT-qPCR measurements were performed 
as previously described71, using primers listed in Supplementary Table S4. To compare by RT-qPCR the mRNA 
levels of ct105 during the developmental cycle of C. trachomatis strains L2/434 or L2/434 harboring pCT105-2HA 
(pSVP264/pCT105-2HA; Supplementary Table S3), a 6-well plate seeded with HeLa 229 cells was inoculated by 
each strain at a multiplicity of infection of 50 and cells were harvested at the indicated times post infection by 
trypsinization. Total RNA was isolated using NZY Total RNA Isolation Kit (NZYtech). For each RNA sample, 
cDNA was generated using iScript cDNA Synthesis Kit (Bio-Rad) accordingly with the manufacturer’s instruc-
tions. RT-qPCR was performed using ct105 and 16S primers (Supplementary Table S4) and SsoFast EvaGreen 
Supermix (Bio-Rad). For each time point, quantitative PCR was performed on each cDNA sample (including an 
RT-negative sample) using Rotor Gene 6000 (Corbett Life Science). For normalization, ratios to the 16s rRNA 
transcript were obtained. Data analysis was carried out with Rotor-Gene 6000 software. Unless otherwise indi-
cated, RT-qPCR results were based in three independent experiments.
Statistical analyses. Statistical analyses were done using GraphPad Prism, version 5.04 for Windows, 
GraphPad Software, San Diego California, USA (www.graphpad.com).
Data Availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files).
References
 1. Taylor, H. R., Burton, M. J., Haddad, D., West, S. & Wright, H. Trachoma. Lancet, https://doi.org/10.1016/S0140-6736(13)62182-0 
(2014).
 2. O’Connell, C. M. & Ferone, M. E. Chlamydia trachomatis Genital Infections. Microb Cell 3, 390–403, https://doi.org/10.15698/
mic2016.09.525 (2016).
 3. Sachse, K. et al. Emendation of the family Chlamydiaceae: proposal of a single genus, Chlamydia, to include all currently recognized 
species. Syst Appl Microbiol 38, 99–103, https://doi.org/10.1016/j.syapm.2014.12.004 (2015).
 4. Elwell, C., Mirrashidi, K. & Engel, J. Chlamydia cell biology and pathogenesis. Nat Rev Microbiol 14, 385–400, https://doi.
org/10.1038/nrmicro.2016.30 (2016).
 5. Galan, J. E., Lara-Tejero, M., Marlovits, T. C. & Wagner, S. Bacterial type III secretion systems: specialized nanomachines for protein 
delivery into target cells. Annu Rev Microbiol 68, 415–438, https://doi.org/10.1146/annurev-micro-092412-155725 (2014).
 6. Mueller, K. E., Plano, G. V. & Fields, K. A. New frontiers in type III secretion biology: the Chlamydia perspective. Infect Immun 82, 
2–9, https://doi.org/10.1128/IAI.00917-13 (2014).
 7. Galan, J. E. Common themes in the design and function of bacterial effectors. Cell Host Microbe 5, 571–579 (2009).
 8. Hicks, S. W. & Galan, J. E. Exploitation of eukaryotic subcellular targeting mechanisms by bacterial effectors. Nat Rev Microbiol 11, 
316–326, https://doi.org/10.1038/nrmicro3009 (2013).
 9. Rockey, D. D., Scidmore, M. A., Bannantine, J. P. & Brown, W. J. Proteins in the chlamydial inclusion membrane. Microbes Infect 4, 
333–340 (2002).
 10. Li, Z. et al. Characterization of fifty putative inclusion membrane proteins encoded in the Chlamydia trachomatis genome. Infect 
Immun 76, 2746–2757 (2008).
13Scientific RepoRts |          (2019) 9:6133  | https://doi.org/10.1038/s41598-019-42647-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
 11. McKuen, M. J., Mueller, K. E., Bae, Y. S. & Fields, K. A. Fluorescence-Reported Allelic Exchange Mutagenesis Reveals a Role for 
Chlamydia trachomatis TmeA in Invasion That Is Independent of Host AHNAK. Infect Immun 85, https://doi.org/10.1128/
IAI.00640-17 (2017).
 12. Carpenter, V., Chen, Y. S., Dolat, L. & Valdivia, R. H. The Effector TepP Mediates Recruitment and Activation of Phosphoinositide 
3-Kinase on Early Chlamydia trachomatis Vacuoles. mSphere 2, https://doi.org/10.1128/mSphere.00207-17 (2017).
 13. Vromman, F., Perrinet, S., Gehre, L. & Subtil, A. The DUF582 Proteins of Chlamydia trachomatis Bind to Components of the ESCRT 
Machinery, Which Is Dispensable for Bacterial Growth In vitro. Frontiers in cellular and infection microbiology 6, 123, https://doi.
org/10.3389/fcimb.2016.00123 (2016).
 14. Thwaites, T. R., Pedrosa, A. T., Peacock, T. P. & Carabeo, R. A. Vinculin Interacts with the Chlamydia Effector TarP Via a Tripartite 
Vinculin Binding Domain to Mediate Actin Recruitment and Assembly at the Plasma Membrane. Frontiers in cellular and infection 
microbiology 5, 88, https://doi.org/10.3389/fcimb.2015.00088 (2015).
 15. Parrett, C. J., Lenoci, R. V., Nguyen, B., Russell, L. & Jewett, T. J. Targeted Disruption of Chlamydia trachomatis Invasion by in Trans 
Expression of Dominant Negative Tarp Effectors. Frontiers in cellular and infection microbiology 6, 84, https://doi.org/10.3389/
fcimb.2016.00084 (2016).
 16. Misaghi, S. et al. Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Mol Microbiol 61, 
142–150 (2006).
 17. Fischer, A. et al. Chlamydia trachomatis-containing vacuole serves as deubiquitination platform to stabilize Mcl-1 and to interfere 
with host defense. eLife 6, https://doi.org/10.7554/eLife.21465 (2017).
 18. Gehre, L. et al. Sequestration of host metabolism by an intracellular pathogen. eLife 5, e12552, https://doi.org/10.7554/eLife.12552 
(2016).
 19. da Cunha, M., Pais, S. V., Bugalhao, J. N. & Mota, L. J. The Chlamydia trachomatis type III secretion substrates CT142, CT143, and 
CT144 are secreted into the lumen of the inclusion. PLoS One 12, e0178856, https://doi.org/10.1371/journal.pone.0178856 (2017).
 20. Fling, S. P. et al. CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia 
trachomatis. Proc Natl Acad Sci USA 98, 1160–1165 (2001).
 21. Fields, K. A. & Hackstadt, T. Evidence for the secretion of Chlamydia trachomatis CopN by a type III secretion mechanism. Mol 
Microbiol 38, 1048–1060 (2000).
 22. Wang, X., Hybiske, K. & Stephens, R. S. Direct visualization of the expression and localization of chlamydial effector proteins within 
infected host cells. Pathogens and disease 76, https://doi.org/10.1093/femspd/fty011 (2018).
 23. Pennini, M. E., Perrinet, S., Dautry-Varsat, A. & Subtil, A. Histone methylation by NUE, a novel nuclear effector of the intracellular 
pathogen Chlamydia trachomatis. PLoS Pathog 6, e1000995, https://doi.org/10.1371/journal.ppat.1000995 (2010).
 24. Muschiol, S. et al. Identification of a family of effectors secreted by the type III secretion system that are conserved in pathogenic 
Chlamydiae. Infect Immun 79, 571–580, https://doi.org/10.1128/IAI.00825-10 (2011).
 25. Hobolt-Pedersen, A. S., Christiansen, G., Timmerman, E., Gevaert, K. & Birkelund, S. Identification of Chlamydia trachomatis 
CT621, a protein delivered through the type III secretion system to the host cell cytoplasm and nucleus. FEMS Immunol Med 
Microbiol 57, 46–58 (2009).
 26. Bullock, H. D., Hower, S. & Fields, K. A. Domain Analyses Reveal That Chlamydia trachomatis CT694 Protein Belongs to the 
Membrane-localized Family of Type III Effector Proteins. J Biol Chem 287, 28078–28086, https://doi.org/10.1074/jbc.M112.386904 
(2012).
 27. da Cunha, M. et al. Identification of type III secretion substrates of Chlamydia trachomatis using Yersinia enterocolitica as a 
heterologous system. BMC Microbiol 14, 40, https://doi.org/10.1186/1471-2180-14-40 (2014).
 28. Pais, S. V., Milho, C., Almeida, F. & Mota, L. J. Identification of novel type III secretion chaperone-substrate complexes of Chlamydia 
trachomatis. PLoS One 8, e56292, https://doi.org/10.1371/journal.pone.0056292 (2013).
 29. Borges, V. & Gomes, J. P. Deep comparative genomics among Chlamydia trachomatis lymphogranuloma venereum isolates 
highlights genes potentially involved in pathoadaptation. Infect Genet Evol 32, 74–88, https://doi.org/10.1016/j.meegid.2015.02.026 
(2015).
 30. Albrecht, M., Sharma, C. M., Reinhardt, R., Vogel, J. & Rudel, T. Deep sequencing-based discovery of the Chlamydia trachomatis 
transcriptome. Nucleic Acids Res 38, 868–877, https://doi.org/10.1093/nar/gkp1032 (2010).
 31. Borges, V., Nunes, A., Ferreira, R., Borrego, M. J. & Gomes, J. P. Directional Evolution of Chlamydia trachomatis Towards Niche-
specific Adaptation. J Bacteriol, https://doi.org/10.1128/JB.01291-12 (2012).
 32. Heuer, D. et al. Chlamydia causes fragmentation of the Golgi compartment to ensure reproduction. Nature 457, 731–735 (2009).
 33. Lippincott-Schwartz, J., Yuan, L. C., Bonifacino, J. S. & Klausner, R. D. Rapid redistribution of Golgi proteins into the ER in cells 
treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 56, 801–813 (1989).
 34. Inoue, T., Heo, W. D., Grimley, J. S., Wandless, T. J. & Meyer, T. An inducible translocation strategy to rapidly activate and inhibit 
small GTPase signaling pathways. Nat Methods 2, 415–418, https://doi.org/10.1038/nmeth763 (2005).
 35. Falcon-Perez, J. M., Nazarian, R., Sabatti, C. & Dell’Angelica, E. C. Distribution and dynamics of Lamp1-containing endocytic 
organelles in fibroblasts deficient in BLOC-3. J Cell Sci 118, 5243–5255, https://doi.org/10.1242/jcs.02633 (2005).
 36. Drozdetskiy, A., Cole, C., Procter, J. & Barton, G. J. JPred4: a protein secondary structure prediction server. Nucleic Acids Res 43, 
W389–394, https://doi.org/10.1093/nar/gkv332 (2015).
 37. Shohdy, N., Efe, J. A., Emr, S. D. & Shuman, H. A. Pathogen effector protein screening in yeast identifies Legionella factors that 
interfere with membrane trafficking. Proc Natl Acad Sci USA 102, 4866–4871, https://doi.org/10.1073/pnas.0501315102 (2005).
 38. Curak, J., Rohde, J. & Stagljar, I. Yeast as a tool to study bacterial effectors. Curr Opin Microbiol 12, 18–23, https://doi.org/10.1016/j.
mib.2008.11.004 (2009).
 39. Franco, I. S., Shohdy, N. & Shuman, H. A. The Legionella pneumophila Effector VipA Is an Actin Nucleator That Alters Host Cell 
Organelle Trafficking. PLoS Pathog 8, e1002546, https://doi.org/10.1371/journal.ppat.1002546 (2012).
 40. Babst, M., Wendland, B., Estepa, E. J. & Emr, S. D. The Vps4p AAA ATPase regulates membrane association of a Vps protein 
complex required for normal endosome function. EMBO J 17, 2982–2993, https://doi.org/10.1093/emboj/17.11.2982 (1998).
 41. Patel, J. C., Hueffer, K., Lam, T. T. & Galan, J. E. Diversification of a Salmonella virulence protein function by ubiquitin-dependent 
differential localization. Cell 137, 283–294 (2009).
 42. Weber, M. M. et al. Absence of Specific Chlamydia trachomatis Inclusion Membrane Proteins Triggers Premature Inclusion 
Membrane Lysis and Host Cell Death. Cell reports 19, 1406–1417, https://doi.org/10.1016/j.celrep.2017.04.058 (2017).
 43. Stanhope, R., Flora, E., Bayne, C. & Derre, I. IncV, a FFAT motif-containing Chlamydia protein, tethers the endoplasmic reticulum 
to the pathogen-containing vacuole. Proc Natl Acad Sci USA 114, 12039–12044, https://doi.org/10.1073/pnas.1709060114 (2017).
 44. Murray, R. Z. & Stow, J. L. Cytokine Secretion in Macrophages: SNAREs, Rabs, and Membrane Trafficking. Front Immunol 5, 538, 
https://doi.org/10.3389/fimmu.2014.00538 (2014).
 45. Gleeson, P. A. The role of endosomes in innate and adaptive immunity. Semin Cell Dev Biol 31, 64–72, https://doi.org/10.1016/j.
semcdb.2014.03.002 (2014).
 46. Nguyen, P. H., Lutter, E. I. & Hackstadt, T. Chlamydia trachomatis inclusion membrane protein MrcA interacts with the inositol 
1,4,5-trisphosphate receptor type 3 (ITPR3) to regulate extrusion formation. PLoS Pathog 14, e1006911, https://doi.org/10.1371/
journal.ppat.1006911 (2018).
 47. Hicks, S. W., Charron, G., Hang, H. C. & Galan, J. E. Subcellular targeting of Salmonella virulence proteins by host-mediated 
S-palmitoylation. Cell Host Microbe 10, 9–20, https://doi.org/10.1016/j.chom.2011.06.003 (2011).
1 4Scientific RepoRts |          (2019) 9:6133  | https://doi.org/10.1038/s41598-019-42647-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
 48. Gruenheid, S. et al. Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of 
enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol 51, 1233–1249 (2004).
 49. Lin, Y. H. et al. Host Cell-catalyzed S-Palmitoylation Mediates Golgi Targeting of the Legionella Ubiquitin Ligase GobX. J Biol Chem 
290, 25766–25781, https://doi.org/10.1074/jbc.M115.637397 (2015).
 50. Bayer-Santos, E. et al. The Salmonella Effector SteD Mediates MARCH8-Dependent Ubiquitination of MHC II Molecules and 
Inhibits T Cell Activation. Cell Host Microbe 20, 584–595, https://doi.org/10.1016/j.chom.2016.10.007 (2016).
 51. Kim, J. et al. The bacterial virulence factor NleA inhibits cellular protein secretion by disrupting mammalian COPII function. Cell 
Host Microbe 2, 160–171, https://doi.org/10.1016/j.chom.2007.07.010 (2007).
 52. Thanabalasuriar, A. et al. The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by 
enteropathogenic Escherichia coli. Cell Microbiol 12, 31–41, https://doi.org/10.1111/j.1462-5822.2009.01376.x (2010).
 53. Yen, H., Sugimoto, N. & Tobe, T. Enteropathogenic Escherichia coli Uses NleA to Inhibit NLRP3 Inflammasome Activation. PLoS 
Pathog 11, e1005121, https://doi.org/10.1371/journal.ppat.1005121 (2015).
 54. Lee, S. F. et al. A C-terminal class I PDZ binding motif of EspI/NleA modulates the virulence of attaching and effacing Escherichia 
coli and Citrobacter rodentium. Cell Microbiol 10, 499–513, https://doi.org/10.1111/j.1462-5822.2007.01065.x (2008).
 55. Thanabalasuriar, A. et al. Sec. 24 interaction is essential for localization and virulence-associated function of the bacterial effector 
protein NleA. Cell Microbiol 14, 1206–1218, https://doi.org/10.1111/j.1462-5822.2012.01789.x (2012).
 56. Yi, C. R. et al. Systematic analysis of bacterial effector-postsynaptic density 95/disc large/zonula occludens-1 (PDZ) domain 
interactions demonstrates Shigella OspE protein promotes protein kinase C activation via PDLIM proteins. J Biol Chem 289, 
30101–30113, https://doi.org/10.1074/jbc.M114.595868 (2014).
 57. Thomson, N. R. et al. Chlamydia trachomatis: genome sequence analysis of lymphogranuloma venereum isolates. Genome Res 18, 
161–171 (2008).
 58. Agaisse, H. & Derre, I. A C. trachomatis cloning vector and the generation of C. trachomatis strains expressing fluorescent proteins 
under the control of a C. trachomatis promoter. PLoS One 8, e57090, https://doi.org/10.1371/journal.pone.0057090 (2013).
 59. Rodriguez-Escudero, I. et al. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochem J 390, 613–623, https://
doi.org/10.1042/BJ20050574 (2005).
 60. de Felipe, K. S. et al. Legionella eukaryotic-like type IV substrates interfere with organelle trafficking. PloS Pathog 4, e1000117, 
https://doi.org/10.1371/journal.ppat.1000117 (2008).
 61. Bauler, L. D. & Hackstadt, T. Expression and targeting of secreted proteins from Chlamydia trachomatis. J Bacteriol 196, 1325–1334, 
https://doi.org/10.1128/JB.01290-13 (2014).
 62. Hammond, G. R. et al. PI4P and PI(4,5)P2 are essential but independent lipid determinants of membrane identity. Science 337, 
727–730, https://doi.org/10.1126/science.1222483 (2012).
 63. Uphoff, C. C. & Drexler, H. G. Detecting mycoplasma contamination in cell cultures by polymerase chain reaction. Methods Mol Biol 
731, 93–103, https://doi.org/10.1007/978-1-61779-080-5_8 (2011).
 64. Scidmore, M. A. Cultivation and Laboratory Maintenance of Chlamydia trachomatis. Curr Protoc Microbiol Chapter 11(Unit 11A), 
11 (2005).
 65. Nguyen, B. D. & Valdivia, R. H. Forward genetic approaches in Chlamydia trachomatis. Journal of visualized experiments: JoVE, 
e50636, https://doi.org/10.3791/50636 (2013).
 66. Johnson, C. M. & Fisher, D. J. Site-specific, insertional inactivation of incA in Chlamydia trachomatis using a group II intron. PloS 
One 8, e83989, https://doi.org/10.1371/journal.pone.0083989 (2013).
 67. Key, C. E. & Fisher, D. J. Use of Group II Intron Technology for Targeted Mutagenesis in Chlamydia trachomatis. Methods Mol Biol 
1498, 163–177, https://doi.org/10.1007/978-1-4939-6472-7_11 (2017).
 68. Darsow, T., Odorizzi, G. & Emr, S. D. Invertase fusion proteins for analysis of protein trafficking in yeast. Methods Enzymol 327, 
95–106 (2000).
 69. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676–682, https://doi.org/10.1038/
nmeth.2019 (2012).
 70. Wesolowski, J. et al. Chlamydia Hijacks ARF GTPases To Coordinate Microtubule Posttranslational Modifications and Golgi 
Complex Positioning. mBio 8, https://doi.org/10.1128/mBio.02280-16 (2017).
 71. Almeida, F. et al. Polymorphisms in Inc Proteins and Differential Expression of inc Genes among Chlamydia trachomatis Strains 
Correlate with Invasiveness and Tropism of Lymphogranuloma Venereum Isolates. J Bacteriol 194, 6574–6585, https://doi.
org/10.1128/JB.01428-12 (2012).
Acknowledgements
We are grateful to Ana Luzia Trindade and to Catarina Milho for the construction of plasmids, and to Agathe 
Subtil and Guangming Zhong for the gift of antibodies. This work was supported by Fundação para a Ciência 
e a Tecnologia (FCT/MCTES) through grants PTDC/IMI-MIC/1300/2014 and PTDC/BIA-MIC/28503/2017, 
and by the Applied Molecular Biosciences Unit (UCIBIO), which is financed by national funds from FCT/
MCTES (UID/Multi/04378/2019) and co-financed by the European Regional Development Fund (ERDF) under 
the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). SVP was supported by PhD fellowship 
PD/BD/52210/2013 within the scope of the PhD program Molecular Biosciences (PD/00133/2012) funded by 
FCT/MCTES. ISP was supported by PhD fellowship SFRH/BD/129756/2017. Work by DJF was funded by grant 
R21AI115238 from the National Institutes of Health.
Author Contributions
S.V.P., J.P.G., D.J.F. and L.J.M. conceived the experiments. S.V.P., C.E.K., V.B., I.S.P. and L.J.M. conducted the 
experiments. S.V.P., V.B., I.S.P., J.P.G., D.J.F. and L.J.M. analyzed the results. S.V.P. and L.J.M. wrote the manuscript, 
which was revised by all authors.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-42647-3.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
1 5Scientific RepoRts |          (2019) 9:6133  | https://doi.org/10.1038/s41598-019-42647-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
